GSK plc (GSK) Stock Competitors & Peer Comparison
See (GSK) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK | $51.76 | -1.91% | 103.7B | 11.18 | $4.63 | +3.49% |
| LLY | $1,179.09 | +0.85% | 1.1T | 40.06 | $29.42 | +0.55% |
| JNJ | $253.04 | +1.23% | 609.1B | 23.58 | $10.73 | +2.07% |
| ABBV | $254.49 | +0.04% | 449.8B | 24.98 | $10.19 | +2.66% |
| MRK | $127.50 | -0.10% | 314.9B | 23.31 | $5.47 | +2.64% |
| NVS | $153.76 | +0.67% | 293.4B | 17.69 | $8.69 | +3.08% |
| NVO | $50.32 | -2.25% | 223.6B | 12.48 | $4.03 | +3.58% |
| AMGN | $366.29 | -1.42% | 197.7B | 16.57 | $22.10 | +2.69% |
| GILD | $134.28 | -1.48% | 166.7B | 16.04 | $8.37 | +2.39% |
| PFE | $25.05 | -0.36% | 142.8B | 8.19 | $3.06 | +6.84% |
Stock Comparison
GSK vs LLY Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GSK is priced at $51.76, while LLY trades at $1,179.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas LLY's P/E ratio is 40.06. In terms of profitability, GSK's ROE is +0.28%, compared to LLY's ROE of +1.01%. Regarding short-term risk, GSK is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check LLY's competition here
GSK vs JNJ Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, JNJ has a market cap of 609.1B. Regarding current trading prices, GSK is priced at $51.76, while JNJ trades at $253.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas JNJ's P/E ratio is 23.58. In terms of profitability, GSK's ROE is +0.28%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GSK is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here
GSK vs ABBV Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, ABBV has a market cap of 449.8B. Regarding current trading prices, GSK is priced at $51.76, while ABBV trades at $254.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas ABBV's P/E ratio is 24.98. In terms of profitability, GSK's ROE is +0.28%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, GSK is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here
GSK vs MRK Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, MRK has a market cap of 314.9B. Regarding current trading prices, GSK is priced at $51.76, while MRK trades at $127.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas MRK's P/E ratio is 23.31. In terms of profitability, GSK's ROE is +0.28%, compared to MRK's ROE of +0.18%. Regarding short-term risk, GSK is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MRK's competition here
GSK vs NVS Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, NVS has a market cap of 293.4B. Regarding current trading prices, GSK is priced at $51.76, while NVS trades at $153.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas NVS's P/E ratio is 17.69. In terms of profitability, GSK's ROE is +0.28%, compared to NVS's ROE of +0.32%. Regarding short-term risk, GSK is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check NVS's competition here
GSK vs NVO Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, NVO has a market cap of 223.6B. Regarding current trading prices, GSK is priced at $51.76, while NVO trades at $50.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas NVO's P/E ratio is 12.48. In terms of profitability, GSK's ROE is +0.28%, compared to NVO's ROE of +0.66%. Regarding short-term risk, GSK is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check NVO's competition here
GSK vs AMGN Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, AMGN has a market cap of 197.7B. Regarding current trading prices, GSK is priced at $51.76, while AMGN trades at $366.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas AMGN's P/E ratio is 16.57. In terms of profitability, GSK's ROE is +0.28%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GSK is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here
GSK vs GILD Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, GILD has a market cap of 166.7B. Regarding current trading prices, GSK is priced at $51.76, while GILD trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas GILD's P/E ratio is 16.04. In terms of profitability, GSK's ROE is +0.28%, compared to GILD's ROE of +0.42%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here
GSK vs PFE Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, PFE has a market cap of 142.8B. Regarding current trading prices, GSK is priced at $51.76, while PFE trades at $25.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas PFE's P/E ratio is 8.19. In terms of profitability, GSK's ROE is +0.28%, compared to PFE's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check PFE's competition here
GSK vs AZN Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, AZN has a market cap of 131B. Regarding current trading prices, GSK is priced at $51.76, while AZN trades at $168.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas AZN's P/E ratio is 18.24. In terms of profitability, GSK's ROE is +0.28%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GSK is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check AZN's competition here
GSK vs BMY Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, BMY has a market cap of 124.1B. Regarding current trading prices, GSK is priced at $51.76, while BMY trades at $60.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas BMY's P/E ratio is 10.24. In terms of profitability, GSK's ROE is +0.28%, compared to BMY's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BMY's competition here
GSK vs SNY Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, SNY has a market cap of 107.4B. Regarding current trading prices, GSK is priced at $51.76, while SNY trades at $44.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas SNY's P/E ratio is 9.73. In terms of profitability, GSK's ROE is +0.28%, compared to SNY's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check SNY's competition here
GSK vs ZTS Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, ZTS has a market cap of 32.1B. Regarding current trading prices, GSK is priced at $51.76, while ZTS trades at $76.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas ZTS's P/E ratio is 11.83. In terms of profitability, GSK's ROE is +0.28%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, GSK is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ZTS's competition here
GSK vs BIIB Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, BIIB has a market cap of 30.4B. Regarding current trading prices, GSK is priced at $51.76, while BIIB trades at $205.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas BIIB's P/E ratio is 13.00. In terms of profitability, GSK's ROE is +0.28%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here
GSK vs HZNP Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $51.76, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.28%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here
GSK vs GRFS Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, GSK is priced at $51.76, while GRFS trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas GRFS's P/E ratio is 8.35. In terms of profitability, GSK's ROE is +0.28%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GSK is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here
GSK vs OGN Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, GSK is priced at $51.76, while OGN trades at $13.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas OGN's P/E ratio is 4.04. In terms of profitability, GSK's ROE is +0.28%, compared to OGN's ROE of +0.30%. Regarding short-term risk, GSK is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check OGN's competition here
GSK vs CELG-RI Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, CELG-RI has a market cap of 241M. Regarding current trading prices, GSK is priced at $51.76, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.28%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, GSK is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check CELG-RI's competition here
GSK vs SCLXW Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, SCLXW has a market cap of 82.2M. Regarding current trading prices, GSK is priced at $51.76, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, GSK's ROE is +0.28%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GSK is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here
GSK vs SCLX Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, SCLX has a market cap of 71.7M. Regarding current trading prices, GSK is priced at $51.76, while SCLX trades at $8.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas SCLX's P/E ratio is -0.22. In terms of profitability, GSK's ROE is +0.28%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here
GSK vs CTOR Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, CTOR has a market cap of 64.1M. Regarding current trading prices, GSK is priced at $51.76, while CTOR trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas CTOR's P/E ratio is -1.47. In terms of profitability, GSK's ROE is +0.28%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, GSK is more volatile compared to CTOR. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check CTOR's competition here
GSK vs MIRA Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, MIRA has a market cap of 40.3M. Regarding current trading prices, GSK is priced at $51.76, while MIRA trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas MIRA's P/E ratio is -0.66. In terms of profitability, GSK's ROE is +0.28%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here
GSK vs CRXT Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $51.76, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.28%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here
GSK vs BDSIW Comparison July 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103.7B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $51.76, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 11.18, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, GSK's ROE is +0.28%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here